Tempest Therapeutics (TPST)
(Delayed Data from NSDQ)
$1.28 USD
+0.02 (1.59%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $1.28 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Income Statements
Fiscal Year end for Tempest Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 29 | 35 | 27 | 36 | 45 |
Income After Depreciation & Amortization | -29 | -35 | -27 | -36 | -45 |
Non-Operating Income | 1 | 1 | 0 | 0 | 0 |
Interest Expense | 1 | 2 | 1 | 0 | -1 |
Pretax Income | -29 | -36 | -28 | -36 | -45 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -29 | -36 | -28 | -36 | -45 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -29 | -36 | -28 | -36 | -45 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -29 | -34 | -27 | -35 | -44 |
Depreciation & Amortization (Cash Flow) | 0 | 1 | 0 | 1 | 1 |
Income After Depreciation & Amortization | -29 | -35 | -27 | -36 | -45 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 15.44 | 11.56 | 3.79 | NA | 0.91 |
Diluted EPS Before Non-Recurring Items | -1.91 | -3.09 | -7.47 | NA | -48.73 |
Diluted Net EPS (GAAP) | -1.91 | -3.09 | -7.47 | -28.94 | -48.73 |
Fiscal Year end for Tempest Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 9.59 | 7.97 | 7.51 | 6.59 | 7.47 |
Income After SG&A, R&D, and Dept/Amort Expenses | -9.59 | -7.97 | -7.51 | -6.59 | -7.47 |
Non-Operating Income | 0.38 | 0.44 | 0.40 | 0.18 | 0.24 |
Interest Expense | 0.37 | 0.37 | 0.38 | 0.37 | 0.36 |
Pretax Income | -9.57 | -7.90 | -7.49 | -6.79 | -7.58 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -9.57 | -7.90 | -7.49 | -6.79 | -7.58 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -9.57 | -7.90 | -7.49 | -6.79 | -7.58 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 22.79 | 21.96 | 15.44 | 14.14 | 14.04 |
Diluted EPS Before Non-Recurring Items | -0.42 | -0.36 | -0.34 | -0.48 | -0.54 |
Diluted Net EPS (GAAP) | -0.42 | -0.36 | -0.34 | -0.48 | -0.54 |